Baxter International Inc vs Centrus Energy Corp — how do they compare? Baxter International Inc trades at $21.78 (market cap $11.26B), while Centrus Energy Corp trades at $160.21 (market cap $3.14B). The key difference: Baxter International Inc is far larger — about 3.6× Centrus Energy Corp's market cap, and Baxter International Inc pays a 0.92% dividend while Centrus Energy Corp pays none. Which is the better fit depends on your goals.
| BAX | LEU | |
|---|---|---|
Market Cap | $11.26B | $3.14B |
Sector | Health | Energy |
52-Week High | $29.22 | $436.00 |
52-Week Low | $15.80 | $146.61 |
Enterprise Value | $18.93B | $2.45B |
Dividend Yield | 0.92% | — |
Signals from Pluang's Aura AI — not financial advice
Baxter International (BAX) trades at $22.57, down 0.22% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q1 2026 earnings beat with $0.36 EPS versus $0.31 expected, though net income margin remains negative at -9.7%. Recent news highlights upcoming Q2 earnings call and sustainability initiatives, while analyst consensus sits at $22.67 price target with 42% buy ratings.
BAX faces fundamental challenges with negative profitability metrics and volatile cash flow, but valuation appears reasonable with P/S of 1.02. The stock offers potential upside to analyst targets if operational improvements materialize, though investors must weigh high debt levels and inconsistent earnings performance against turnaround prospects in the medical technology sector.
Centrus Energy (LEU) trades at $156.05, down 8.77% over 24 hours amid bearish technical signals. The stock shows mixed fundamentals with a high P/E of 57.96 but strong net income margin of 13.4%. Recent positive developments include a $1 billion DOE contract expansion and inclusion in the S&P SmallCap 600 index, though earnings have been inconsistent with two misses and one beat in recent quarters.
The outlook remains cautiously optimistic given strong government contracts and nuclear industry tailwinds, but elevated valuation and recent earnings volatility present risks. Analyst consensus price target of $223.14 suggests 43% upside potential, though technical indicators signal near-term bearish pressure with support at $151.
Trailing returns across standard periods
Latest headlines on both assets
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.
Read more on LEU →